-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Most of the histological type of renal cell carcinoma (RCC) is clear cell carcinoma, and a small part may be a sarcoma-like type, that is, sarcomatoid renal cell carcinoma (sRCC).
This article aims to evaluate the efficacy of avelumab combined with axitinib or sunitinib in untreated patients with advanced sRCC .
This article aims to evaluate the efficacy of avelumab combined with axitinib or sunitinib in untreated advanced sRCC patients with sunitinib
The JAVELIN Renal 101 study is a randomized, open-label, multi-center phase III clinical trial.
Comparison of the prognosis of the two groups of patients
Comparison of the prognosis of the two groups of patientsA total of 108 sRCC patients were included in this post-hoc analysis: 47 were treated with avelumab + axitinib, and 61 were treated with avelumab + sunitinib.
Compared with sunitinib group, Asif for progression-free survival in patients with non-Nepalese groups and objective response rate were significantly increased
Related gene expression analysis
Related gene expression analysisAnalysis of related gene expression in sRCC patients showed that fibroblasts and regulatory T cells related to cancer, CD274 and CD8A expression, and tumor gene pathways classified by Atlas m3 of the oncogenome were significantly richer.
The subgroup analysis of the JAVELIN Renal 101 trial showed that the efficacy and prognosis of sRCC patients treated with avelumab combined with axitinib was significantly higher than that of patients treated with avelumab combined with sunitinib .
The efficacy and prognosis of sRCC patients treated with avelumab and axitinib were significantly improved compared with patients treated with avelumab and sunitinib Significantly improved
Original source:
Original source:Choueiri TK, Larkin J, Pal S et al.
org/10.
1016/j.
esmoop.
2021.
100101" target="_blank" rel="noopener">Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial in this message
